Regencell Bioscience
17 hedge funds and large institutions have $11.5M invested in Regencell Bioscience in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
6% more funds holding
Funds holding: 16 → 17 (+1)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.02% less ownership
Funds ownership: 0.13% → 0.11% (-0.02%)
43% less call options, than puts
Call options by funds: $895K | Put options by funds: $1.58M
63% less capital inflows, than outflows
Capital inflows: $796K | Capital outflows: $2.14M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$290K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$213K |
| 3 |
Vident Advisory
Alpharetta,
Georgia
|
+$193K |
| 4 |
EverSource Wealth Advisors
Birmingham,
Alabama
|
+$8.94K |
| 5 |
Quarry LP
New York
|
+$7.61K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Discovery Capital Management
South Norwalk,
Connecticut
|
-$713K |
| 2 |
Squarepoint
New York
|
-$410K |
| 3 |
XTX Topco
George Town,
Cayman Islands
|
-$385K |
| 4 |
Morgan Stanley
New York
|
-$267K |
| 5 |
Jane Street
New York
|
-$173K |
RGC Hedge Fund Activity: Q4 2025 in Review
17 of the 8,302 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q4 2025, worth a combined $11.5M — up 18% from $9.8M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new RGC positions and 6 closed out — a net gain of 1 holder — while 4 added to existing stakes and 4 trimmed.
The largest buyer was UBS Group, adding an estimated $290K. The largest seller was Discovery Capital Management, exiting entirely with an estimated $713K sold.
- 17 institutional investors held Regencell Bioscience (RGC) as of Q4 2025, up from 16 in Q3 2025.
- Funds reported $11.5M of Regencell Bioscience stock for Q4 2025, up 18% quarter-over-quarter.
- 7 funds opened new Regencell Bioscience positions in Q4 2025 and 6 closed out, a net change of +1 holder.
- The largest Regencell Bioscience buyer in Q4 2025 was UBS Group, an estimated $290K added.
- The largest Regencell Bioscience seller in Q4 2025 was Discovery Capital Management, an estimated $713K sold.
Based on aggregated 13F filings for Q4 2025.